Salbutamol in Congenital Myasthenic Syndrome: A Systematic Review
Abstract Background Congenital myasthenic syndromes (CMS) are inherited disorders of neuromuscular transmission with few effective treatments. Salbutamol, a β2-adrenergic agonist, has shown anecdotal benefit, yet no comprehensive assessment of its clinical effectiveness across genetic subtypes exist...
I tiakina i:
| Ngā kaituhi matua: | , , , , , , |
|---|---|
| Hōputu: | Artigo |
| Reo: | Inglês |
| I whakaputaina: |
BMC
2025-12-01
|
| Rangatū: | BMC Neurology |
| Ngā marau: | |
| Urunga tuihono: | https://doi.org/10.1186/s12883-025-04569-8 |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|